ArticleNature medicine2021
Transcriptional mediators of treatment resistance in lethal prostate cancer.
Open access · hybridAbstract read
In one paragraph
Article in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 1 pooled it
22.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 1 synthesis or guideline pooled it, 188 citations in OpenAlex.
- The positive relationship between androgen receptor splice variant-7 expression and the risk of castration-resistant prostate cancer: A cumulative analysis.Frontiers in oncology · 2023Pooled it
- IRE1 activity is prognostic in localised and metastatic prostate cancer and affects epithelial lineage states.EMBO molecular medicine · 2026Article
- Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of '-mabs'?The Journal of pathology · 2026Review
- Single-cell and spatial RNA sequencing in prostate cancer.Nature reviews. Urology · 2026Review
- Systematic identification of genomic nonresponse biomarkers to cancer therapies.ESMO real world data and digital oncology · 2026Article
- Increasing Cancer Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival.bioRxiv : the preprint server for biology · 2026Article
- Human Group IIA Secreted Phospholipase AInternational journal of molecular sciences · 2026Review
- A Non-Canonical Core Transcriptional Regulatory Circuit Orchestrates Chromatin Reprogramming to Drive Osimertinib Resistance in Non-Small Cell Lung Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Decoding 3D chromatin architecture reveals distinct enhancer classes underlying hierarchical gene regulation in prostate cancer.Genome biology · 2026Article
- A non-enzymatic role for METTL3 as an Androgen Receptor co-regulator that promotes prostate cancer proliferation.bioRxiv : the preprint server for biology · 2026Article
- The FOSB-IGFBP5-IGF-1 axis: a novel regulatory pathway that suppresses prostate cancer growth.Cancer gene therapy · 2026Article
- A harmonized single-cell RNA-seq atlas of human localized and metastatic prostate cancers and benign tissues.bioRxiv : the preprint server for biology · 2026Article
- Dependencies in heterogeneous, lineage plastic patient-derived prostate cancer organoids revealed through integrated single-cell multiomics and CRISPR screening.bioRxiv : the preprint server for biology · 2026Article
- Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.The Journal of clinical investigation · 2026Article
- FOXA1 loss drives basal/squamous de-differentiation of prostate cancer and induces an immunosuppressive tumor microenvironment.Nature communications · 2026Article
- Multi-omics evaluation of cell lines as models for metastatic prostate cancer.Communications biology · 2026Article
- Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy.EMBO molecular medicine · 2026Article
- Arrhythmic expression signatures of circadian clock-associated transcription factors and chronic circadian disruption contribute to advanced prostate cancer growth.International journal of cancer · 2026Article
- Review
- HOXB5 in precision oncology: regulatory networks, functional duality, and clinical prospects.Journal of translational medicine · 2026Review
72 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 7 institutions in 1 country.
Meng Xiao HeHarvard Graduate Program in Biophysics, Boston, MA, USA.
Michael S CuocoBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Jett CrowdisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Alice Bosma-MoodyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Zhenwei ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kevin BiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Abhay KanodiaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Mei-Ju SuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sheng-Yu KuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4715-1888
Maria Mica GarciaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Amalia R SweetDepartment of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Christopher RodmanBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Laura DelloStrittoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0295-0010
Rebecca SilverDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
John SteinharterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Parin ShahDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Benjamin IzarColumbia Center for Translational Immunology, New York, NY, USA.ORCID http://orcid.org/0000-0003-2379-6702
Nathan C WalkDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kelly P BurkeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2187-0147
Ziad BakounyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1906-5704
Alok K TewariDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2617-7499
David LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sabrina Y CampDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Natalie I VokesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3766-5335
Keyan SalariBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Jihye ParkDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sébastien VigneauDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Lawrence FongDivision of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-6428-428X
Joshua W RussoDepartment of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5481-0090
Xin YuanDepartment of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Steven P BalkDepartment of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4546-7371
Himisha BeltranDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3259-2226
Orit Rozenblatt-RosenBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6313-3570
Aviv RegevBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-3293-3158
Asaf RotemDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Mary-Ellen TaplinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. eliezerm_vanallen@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-0201-4444
Broad Institute · USDana-Farber Cancer Institute · USBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USColumbia University Irving Medical Center · USMemorial Medical Center · USUniversity of California, San Francisco · US
Funding
Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1MMOLECULAR BIOPHYSICS TRAINING GRANTT32GM008313 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MURTHY, VENKATESH N · 1989 to 2023
$14.6MMolecular and immune drivers of immunotherapy responsiveness in prostate cancerU01CA233100 · NCI · DANA-FARBER CANCER INST · PI FONG, LAWRENCE, VAN ALLEN, ELIEZER M · 2018 to 2022
$4.2MMolecular mechanisms underlying lineage plasticity in prostate cancerR37CA241486 · NCI · DANA-FARBER CANCER INST · PI Himisha Beltran · 2020 to 2026
$4.1MIntegrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid TumorsR01CA227388 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2022
$2.0MDissecting Therapeutic Resistance and Progression in Metastatic Melanoma Through Clinical Computational OncologyK08CA234458 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LIU, DAVID · 2018 to 2022
$1.2MDeterminants of prostate cancer sensitivity to PD-1 blockadeR01CA223484 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FONG, LAWRENCE · 2018 to 2021
$1.1MDissecting mechanisms of immunotherapy resistance in melanoma patientsK08CA222663 · NCI · DANA-FARBER CANCER INST · PI IZAR, BENJAMIN · 2017 to 2021
$827kHoward Hughes Medical InstituteNCI NIH HHS K08 CA222663NCI NIH HHS K08 CA234458NCI NIH HHS R01 CA223484NCI NIH HHS R01 CA227388NCI NIH HHS R37 CA241486NCI NIH HHS T32 CA009172NCI NIH HHS U01 CA233100NIGMS NIH HHS T32 GM008313
Abstract
Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or acquired resistance to second-generation androgen-targeting therapies and minimal response to immune checkpoint inhibitors
Indexed as
Antineoplastic AgentsBiopsyCD8-Positive T-LymphocytesDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionHumansMaleProstatic Neoplasms, Castration-ResistantReceptors, AndrogenTranscription, GeneticAntineoplastic AgentsAR protein, humanReceptors, Androgen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.